{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:17:31Z","timestamp":1783595851473,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lecanemab approval in the European Union (EU) was granted after a delay. This delay resulted in concerns from many stakeholders, but attitudes of patients with early symptomatic Alzheimer\u2019s disease receiving specialist memory-clinic care remained insufficiently assessed. Therefore, we evaluated attitudes of specialist memory-clinic patients with early symptomatic Alzheimer\u2019s disease towards lecanemab in Europe. In this anonymous, international, multicentre, cross-sectional survey conducted from October 14, 2024 to February 18, 2025, a standardized, expert-developed questionnaire assessed attitudes towards lecanemab treatment and EU approval. Before answering four binary questions, participants received brief explanatory information on expected clinical benefit, amyloid-related imaging abnormalities (ARIA), and the increased ARIA risk associated with APOE \u03b54 homozygosity. The survey was conducted in specialist memory clinics within the European Alzheimer\u2019s Disease Consortium (EADC), the German memory clinic network (DNG), and Austrian memory centers. Available recruitment-flow data were limited to completed questionnaires because the survey was anonymous and distributed locally. 281 patients with early symptomatic Alzheimer\u2019s disease completed the survey. Network-level sample sizes were EADC n\u2009=\u2009202, DNG n\u2009=\u200960, and Austria n\u2009=\u200919; country-specific sample sizes within the EADC and response rates were not available. Endorsement was high for both individual treatment with lecanemab (81.9%, 95% confidence interval [CI] 76.8\u201386.2) and general EU approval (91.8%, 95% CI 87.9\u201394.7). Endorsement remained substantial, but was lower, in the context of APOE \u03b54 homozygosity (treatment: 61.2%, 95% CI 55.2\u201366.9; approval: 76.5%, 95% CI 71.1\u201381.3). Approval-related questions received higher endorsement than treatment-related questions (84% vs. 72%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Support for approval for APOE \u03b54 homozygotes declined after regulatory recommendations excluded this group (from 87% to 73%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.025); this comparison reflects independent respondents completing the anonymous survey before versus after November 14, 2024. Network-level comparisons were descriptive and underpowered for geographic inference. High endorsement within this specialist memory-clinic sample suggests perceived value of access to lecanemab. Greater endorsement for approval than for individual treatment may reflect support for treatment access beyond personal treatment choice, but alternative explanations such as social desirability, acquiescence, misunderstanding, or effects of the survey information cannot be excluded. The findings should not be generalized beyond specialist memory-clinic patients and should be interpreted in view of potential selection and response biases, absent response-rate data, and the brief, non-validated binary questionnaire.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-61640-1","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:04:15Z","timestamp":1783591455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer\u2019s disease towards lecanemab: results from a multicenter survey in Europe"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-838X","authenticated-orcid":false,"given":"Jonathan","family":"V\u00f6glein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"St\u00f6gmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Haass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"1","key":"61640_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388(1), 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"61640_CR2","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 3 Nov 2025."},{"key":"61640_CR3","unstructured":"https:\/\/www.eisai.com\/news\/2023\/news202359.html. Accessed 3 Nov 2025."},{"key":"61640_CR4","unstructured":"https:\/\/www.eisai.com\/news\/2024\/news202403.html. Accessed 3 Nov 2025."},{"key":"61640_CR5","unstructured":"https:\/\/www.eisai.com\/news\/2024\/news202436.html. Accessed 3 Nov 2025."},{"key":"61640_CR6","unstructured":"https:\/\/www.eisai.com\/news\/2024\/news202449.html. Accessed 3 Nov 2025."},{"key":"61640_CR7","unstructured":"https:\/\/www.eisai.com\/news\/2024\/news202451.html. Accessed 3 Nov 2025."},{"key":"61640_CR8","unstructured":"https:\/\/www.eisai.com\/news\/2024\/news202460.html. Accessed 3 Nov 2025."},{"key":"61640_CR9","unstructured":"https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease. Accessed 3 Nov 2025."},{"key":"61640_CR10","unstructured":"https:\/\/ec.europa.eu\/newsroom\/sante\/items\/879055\/en. Accessed 3 Nov 2025."},{"issue":"5","key":"61640_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.14283\/jpad.2024.153","volume":"11","author":"F Jessen","year":"2024","unstructured":"Jessen, F. et al. Progress in the treatment of Alzheimer\u2019s disease is needed\u2014Position statement of European Alzheimer\u2019s Disease Consortium (EADC) investigators. J. Prev. Alzheimers Dis. 11(5), 1212\u20131218 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"61640_CR12","unstructured":"https:\/\/www.sciencemediacentre.org\/expert-reaction-to-ema-decision-on-lecanemab-for-alzheimers-disease. Accessed 3 Nov 2025."},{"key":"61640_CR13","doi-asserted-by":"crossref","unstructured":"Divisions over lecanemab: Keeping an open mind. Lancet 404(10458), 1077 (2024).","DOI":"10.1016\/S0140-6736(24)02075-0"},{"key":"61640_CR14","unstructured":"https:\/\/dgn.org\/artikel\/dgn-bedauert-chmp-empfehlung-gegen-die-ema-zulassung-des-ersten-alzheimer-antikorpers-in-europa. Accessed 3 Nov 2025."},{"key":"61640_CR15","unstructured":"https:\/\/www.dgppn.de\/presse\/pressemitteilungen\/pressemitteilungen-2023\/alzheimer-behandlung-antikoerper-therapie-darf-betroffenen-nicht-verwehrt-werden.html. Accessed 3 Nov 2025."},{"key":"61640_CR16","unstructured":"https:\/\/www.dzne.de\/en\/im-fokus\/meldungen\/2024\/the-decision-is-incomprehensible-statements-of-dzne-experts-on-the-refusal-of-lecanemab-by-european-medicines-agency\/. Accessed 3 Nov 2025."},{"key":"61640_CR17","unstructured":"https:\/\/www.alzheimer-europe.org\/news\/26-july-alzheimer-europe-regrets-negative-european-medicines-agency-opinion-lecanemab-may?language_content_entity=en. Accessed 3 Nov 2025."},{"key":"61640_CR18","unstructured":"https:\/\/www.alzheimer-europe.org\/news\/alzheimer-europe-responds-negative-opinion-lecanemab-european-medicines-agency. Accessed 3 Nov 2025."},{"key":"61640_CR19","unstructured":"https:\/\/www.alzheimer-europe.org\/news\/our-member-organisations-react-ema-opinion-lecanemab. Accessed 3 Nov 2025."},{"key":"61640_CR20","unstructured":"https:\/\/www.eisai.com\/news\/2024\/news202455.html. Accessed 3 Nov 2025."},{"key":"61640_CR21","unstructured":"https:\/\/www.zeit.de\/gesundheit\/2024-07\/alzheimer-therapie-lecanemab-patienten-studie. Accessed 3 Nov 2025."},{"key":"61640_CR22","unstructured":"https:\/\/english.elpais.com\/science-tech\/2024-09-25\/a-scientific-rebellion-to-get-europe-to-approve-a-controversial-alzheimers-drug.html. Accessed 3 Nov 2025."},{"issue":"1","key":"61640_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig, L. S. et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res. Ther. 16(1), 105 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"61640_CR24","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi. Accessed 3 Nov 2025."},{"key":"61640_CR25","unstructured":"https:\/\/deutschesnetzwerkgedachtnisambulanzen.clubdesk.com\/verein\/sektionen. Accessed 3 Nov 2025."},{"key":"61640_CR26","unstructured":"https:\/\/eadc.online\/member-list\/#1669493220960-e5696535-de6f. Accessed 3 Nov 2025."},{"issue":"3","key":"61640_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11673-023-10241-y","volume":"20","author":"A Olchowska-Kotala","year":"2023","unstructured":"Olchowska-Kotala, A., Strz\u0105da\u0142a, A. & Bara\u0144ski, J. Patients\u2019 values and desire for autonomy: An empirical study from Poland. J. Bioeth. Inq. 20(3), 409\u2013419 (2023).","journal-title":"J. Bioeth. Inq."},{"issue":"6","key":"61640_CR28","doi-asserted-by":"publisher","first-page":"e018977","DOI":"10.1136\/bmjopen-2017-018977","volume":"8","author":"RL Daly","year":"2018","unstructured":"Daly, R. L., Bunn, F. & Goodman, C. Shared decision-making for people living with dementia in extended care settings: A systematic review. BMJ Open 8(6), e018977 (2018).","journal-title":"BMJ Open"},{"issue":"5","key":"61640_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/1471301214555542","volume":"15","author":"LM Miller","year":"2016","unstructured":"Miller, L. M., Whitlatch, C. J. & Lyons, K. S. Shared decision-making in dementia: A review of patient and family carer involvement. Dementia 15(5), 1141\u20131157 (2016).","journal-title":"Dementia"},{"issue":"4","key":"61640_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.14283\/jpad.2023.84","volume":"10","author":"S Roldan Munoz","year":"2023","unstructured":"Roldan Munoz, S. et al. Preferences about future Alzheimer\u2019s disease treatments elicited through an online survey using the threshold technique. J. Prev. Alzheimers Dis. 10(4), 756\u2013764 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"61640_CR31","unstructured":"https:\/\/www.ema.europa.eu\/en\/partners-networks\/patients-consumers. Accessed 3 Nov 2025."},{"issue":"2","key":"61640_CR32","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/trc2.12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement (N Y). 10(2), e12465 (2024).","journal-title":"Alzheimers Dement (N Y)."},{"issue":"6","key":"61640_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6), 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"61640_CR34","unstructured":"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease. Accessed 3 Nov 2025."},{"key":"61640_CR35","unstructured":"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-japan-treatment-early. Accessed 3 Nov 2025."},{"key":"61640_CR36","unstructured":"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-china-treatment-early. Accessed 3 Nov 2025."},{"key":"61640_CR37","unstructured":"https:\/\/www.gov.uk\/government\/news\/donanemab-licensed-for-early-stages-of-alzheimers-disease-in-adult-patients-who-have-one-or-no-copies-of-apolipoprotein-e4-gene. Accessed 3 Nov 2025."},{"key":"61640_CR38","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisunla. Accessed 3 Nov 2025."},{"key":"61640_CR39","unstructured":"https:\/\/health.ec.europa.eu\/latest-updates\/commission-authorises-medicine-treat-early-stages-alzheimers-disease-2025-09-25. Accessed 3 Nov 2025."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61640-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:28:21Z","timestamp":1783592901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61640-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61640"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61640-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Competing interests\n                      Jonathan V\u00f6glein received consulting fees, speaker fees, research support, and\/or coverage for conference and travel expenses from Novo Nordisk, Biogen, Eisai, Lilly, the Alzheimer\u2019s Association, the Austrian Alzheimer\u2019s Society, the German Society of Nuclear Medicine, Helmholtz and LMUexcellent. All relationships outside the submitted work. Johannes Levin reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Merck and Roche, consulting fees from Axon Neuroscience, EISAI and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent \u201cOral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies\u201d (PCT\/EP2024\/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent \u201cPharmaceutical Composition and Methods of Use\u201d (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work. Elisabeth St\u00f6gmann\u2019s institution received financial support by research grants for research in AD: Eisai, EU Horizon 2020, Austrian Research Promotion Agency. Her institution received financial support for participation in clinical trials from Biogen, Novo Nordisk and Roche Diagnostics. She received honoraria (consultations, lectures, speakers bureaus, educational events, advisory boards) from pharmaceutical companies: Biogen, Roche, Novo Nordisk, Eisai, Novartis, Sanofi and Lilly. She held leadership in scientific societies: Austrian Alzheimer Association. All relationships outside the submitted work. Christian Haass collaborates with Denali Therapeutics and is a member of the advisory boards of AviadoBio, Cure Ventures, and Curie.Bio. G\u00fcnter H\u00f6glinger serves as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon. Lutz Fr\u00f6lich received honoraria for consulting and for lectures from Biogen, Eisai, GE Healthcare, Grifols, Hummingbird, Janssen-Cilag, Eli Lilly, MerckSharpe&Dohme, Neurimmune, Noselab, Novo Nordisk, Hoffmann-LaRoche, TauRX, Schwabe. All relationships outside the submitted work. Frank Jessen received honoraria for advisory boards and presentations from Abbvie, AC immune, Biogen, Eli Lilly, Eisai, GE Healthcare, Grifols, Janssen-Cilag and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21414"}}